NICE backtracks on green light for Amgen's Xgeva after change of comparators
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is rethinking its initial draft yes for Amgen's bone drug Xgeva (denosumab) for preventing skeletal related events in prostate cancer patients with bone metastases. The draft no comes after NICE's appraisal committee decided that best supportive care would be a more suitable comparator in prostate cancer patients rather than bisphosphonates.